DEVA:IST
Deva Holding AS
77,10 TRY
arrow_upward
+1,98%(+1,50) 1d
20 d’oct., 18:10:00 GMT+3 · TRY
search
Tots els símbols
| Símbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadístiques principals per a DEVA...
Obre
75,60 TRY
Alt
77,20 TRY
Baix
74,50 TRY
Capitalització borsària
15,42 kM
Volum mitjà
590,01 k
Volum
353,94 k
Alt 52 setmanes
109,30 TRY
Baix 52 setmanes
57,50 TRY
BPA
-4,21 TRY
Accions en circulació
200,02 M
Nombre d'empleats
3 k
Obre
75,60 TRY
Alt
77,20 TRY
Baix
74,50 TRY
Capitalització borsària
15,42 kM
Volum mitjà
590,01 k
Volum
353,94 k
Alt 52 setmanes
109,30 TRY
Baix 52 setmanes
57,50 TRY
BPA
-4,21 TRY
Accions en circulació
200,02 M
Nombre d'empleats
3 k
Notícies
De fonts web i partners de notícies
Rosario Finanzas
·
fa 3 hores
Las cartas de Magic impulsan a Hasbro y es la segunda acción que más sube hoy en el S&P 500
ChartMill
·
fa 31 minuts
East West Bancorp (NASDAQ:EWBC) Posts Record Q3 Revenue Beat With In-Line EPS and No Guidance
StockStory
·
fa 28 minuts
Netflix (NASDAQ:NFLX) Posts Q3 2026 Sales In Line With Estimates But Quarterly Revenue Guidance Slightly Misses Expectations
Stock Titan
·
fa 58 minuts
After 30 business days below $1, Dogness (NASDAQ: DOGZ) gets time to regain compliance.
Perfil
DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements.
A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas.
As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
Sobre Deva Holding AS